KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug, Ekterly, for a type of ...

KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug for a type of hereditary swelling disorder, sending its shares up 33.3% in premarket trading.

The cold water swelling starch market is projected to grow from USD 701.2 million in 2025 to USD 1,338.1 million by 2035, ...